Definium Therapeutics, Inc. reported $4.7M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.7M (to Q4 2023). Net income: −$354M, trailing twelve months to Q2 2026. EPS: −$3.43, trailing twelve months to Q2 2026. ROIC: 269%, trailing twelve months to Q2 2026.

DFTXDefinium Therapeutics, Inc.

Healthcare

$36.91+308% 1Y

$36.91

$9.5452 weeks$47.08

DFTX as reported

Definium Therapeutics, Inc. reported $4.7M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$4.7M

Revenue, trailing twelve months · to Q4 2023 · every figure below is as filed, with no scoring applied

Net income: −$354M
Net income · +209% year on year · trailing twelve months to Q2 2026
EPS: −$3.43
EPS · +123% year on year · trailing twelve months to Q2 2026
ROIC: 269%
ROIC · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DFTX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.7M	n/a	Q4 2023 · 10 quarters behind
Net income	−$354M	+209%	Q2 2026
EPS	−$3.43	+123%	Q2 2026
Operating margin	−2041%	n/a	Q4 2023 · 10 quarters behind
Net margin	−2083%	n/a	Q4 2023 · 10 quarters behind
ROE	−77%	n/a	Q2 2026
ROA	−51%	n/a	Q2 2026
ROIC	269%	n/a	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.